DIA Drug Information Association.

From Verify.Wiki
Jump to: navigation, search

For more than 50 years, DIA (the Drug Information Association) has served as a global forum for all those involved in healthcare product development and life cycle management to exchange knowledge and collaborate in a neutral setting. DIA is an essential resource that provides opportunities to extend debate and discussion to advance scientific and medical innovation and the only global organization dedicated to bringing healthcare product development professionals together in a neutral environment to improve health and well-being throughout the world. DIA is based in Washington, DC (US) with regional offices representing the Americas (Horsham, PA, US); Europe, Africa, and the Middle East (Basel, Switzerland); and Asia (Beijing and Shanghai, China; Mumbai, India; and Tokyo, Japan). [1][2]

GI 139678 DIALogo.png
DIA Drug Information Association
Type Public / Private
Industry Pharmaceuticals
Founded 1964
Headquarters 21 Dupont Circle NW Suite 300 Washington, DC 20036
Key people Tatsuo Kurokawa (President)
John A. Roberts (CEO and Executive Vice President of Finance)
Barbara Lopez Kunz (Global Chief Executive)
Number of employees 51-200


DIA was founded in 1964 as a neutral global membership association dedicated to improving communication and collaboration in drug development. That goal remains the same today.

The organization was born out of a true need. DIA’s founding was closely tied to the 1962 passage of sweeping legislation passed in the United States in response to the finding that use of thalidomide to treat morning sickness caused birth defects. Although the problem was global, there was no organization at the time that could foster cooperative efforts across the entire world. Seeing the need, a group of 30 pharmaceutical professionals, medical writers, and academics created DIA as a fully independent unbiased association.

The neutral posture of DIA encourages active participation. Because membership spans all aspects of health care product development and life cycle management, members are free to collaborate fully as they explore fresh ideas and think outside of their traditional fields. Today, DIA is a worldwide organization in more than 80 countries with regional offices covering the Americas, Europe, Asia, the Middle East, and Africa. [3]

DIA Mission

DIA fosters innovation to improve health and well-being worldwide by:

  • Providing invaluable forums to exchange vital information and discuss current issues related to health care products, technologies, and services;
  • Delivering customized learning experiences,
  • Building, maintaining and facilitating trusted relationships with and among individuals and organizations that drive and share DIA values and mandates, and
  • Offering a multidisciplinary neutral environment, respected globally for integrity and relevancy. [4]

DIA Vision

DIA is your essential partner in catalyzing knowledge creation and sharing to accelerate health care product development. [5]


Top 5 Recent Tweets

October 21, 2021eClinical_SolOn October 27, join eClinical CEO @Raj Indupuri at the @DrugInfoAssn event #DTCT21. He'll address the areas being e… https://t.co/RLGXrG7AfR
October 21, 2021CPathInstituteLess than a week to the @DrugInfoAssn #DigitalTechnology in #ClinicalTrials Conference, co-sponsored by #CPath’s e… https://t.co/HwD6B5d0hG
October 20, 2021DrugInfoAssnWith over 20 years in long-term care, @PointClickCare has amassed a significant #database of patient therapy and tr… https://t.co/w4ONAHPqfw
October 20, 2021ClinerionCan we leverage #RWD from #EHRs to create insights into patient care regimens, journeys & outcomes? Join the Cliner… https://t.co/QqcX6au62E
October 20, 2021CurebaseDCTWatch Adam Samson, Sr. Director of ClinOps, discuss two case studies in which #telemedicine was applied in our… https://t.co/gSmTeucQSL

Top 5 Recent News Headlines

  • February 27, 2017 - DIA EuroMeeting Explores the Road Ahead for Drug Development in the EU and UK - DIA, (founded as the Drug Information Association) announced critical workshops to be held at the 2017 DIA EuroMeeting on March 29-31, 2017 at the SECC, Glasgow. The goal of the annual DIA EuroMeeting has always been to stimulate solutions by bringing together diverse stakeholder perspectives on issues affecting drug development in Europe. [6] [7]
  • February 25, 2017 - DIA to organize pharmacovigilance conference on March 24 & 25 in Mumbai - The Drug Information Association (DIA) India is organizing its flagship PV conference “PV –Fast Forward”-Technology, Pace and Priority. The event will be held on March 24 and 25, 2017 at the Hotel The Lalit, Mumbai. The two-day event will have Moin Don, CEO and President, PVCON as The Chair and Krishna Bahadur Singh, senior vice president, safety& risk management, business unit, ARIS Global LLC & Representative Director, AGKK, Tokyo, Japan as the vice chair. Programme will highlight Label Management & Risk Management, Automation in PV, Compliance Management in PV, Latest Regulations in PV, advanced Technologies to Handle Safety Data, delve on the importance of technology in bringing about higher patient safety. [8]

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines


  1. http://www.diaglobal.org/about-us
  2. https://www.linkedin.com/company-beta/384676/?pathWildcard=384676
  3. http://www.diaglobal.org/about-us
  4. http://www.diaglobal.org/about-us
  5. http://www.diaglobal.org/about-us#mission
  6. http://www.businesswire.com/news/home/20170226005063/en/DIA-EuroMeeting-Explores-Road-Drug-Development-EU
  7. http://www.diaglobal.org/en/flagship/euromeeting/program/search-program
  8. http://www.pharmabiz.com/NewsDetails.aspx?aid=100549&sid=1

Verification history